- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05975151
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
September 18, 2023 updated by: Qilu Hospital of Shandong University
Efficacy and Safety of Pseudomonas Aeruginosa Followed by Postoperative Intravesical Instillation in Patients With Intermediate and High-risk Non-muscle Invasive Bladder Cancer: a Multi-center, Single-arm Clinical Study
This is a multicenter, single-arm study to evaluate the efficacy and safety of Pseudomonas aeruginosa the treatment of patients with intermediate and high risk non-muscle invasive bladder cancer.
The study continued treatment until the patient could not obtain clinical benefits or had intolerable toxic reactions or the patient withdrew the informed consent, whichever occurred first.
Study Overview
Detailed Description
This study used a multicenter open single-arm study design.
Study start: March 2023 Study end: March 2024 Multi-center: Three centers were selected to conduct the study to avoid differences in efficacy due to differences in operation among centers.
Single-arm study: A total of 63 subjects with intermediate-high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study.
The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT.
After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected.
The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes.
The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total.
Patients were followed up every 3 months after surgery.
The last follow-up was completed in February 2025.
Study Type
Interventional
Enrollment (Estimated)
63
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Benkang Shi, Dr.
- Phone Number: 18560083917
- Email: bkang68@sdu.edu.cn
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 276600
- Recruiting
- Qilu hospital
-
Contact:
- Benkang Shi
- Phone Number: bkang68@sdu.edu.cn
- Email: bkang68@sdu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- Age ≥18 years old, both male and female;
- Diagnosed as Intermediate or high risk non-muscle invasive bladder cancer, with previous recurrent pathological diagnosis report and cystoscopy available. Intermediate risk was defined as the presence of one or two of the following: multiple tumors, single tumor larger than 3cm, and/or recurrence (≥1 event in low-risk NMIBC within 1 year after diagnosis). High risk was defined as meeting any one of the following: T1 tumor, G3 tumor, carcinoma in situ (CIS), multiple, recurrent and large (> 3cm) TaG1G2/ low-risk tumor (simultaneous);
- Not receiving BCG or other immune drug infusion chemotherapy at the same time
- Informed consent and signed informed consent form by patients and their families;
- Clear consciousness and able to answer questions independently, Patients were asked to complete the questionnaire by themselves;
- No history of neurological diseases, severe hematological diseases, and dysfunction of heart, lung, liver, or kidney were observed.
Exclusion criteria:
- Patients with other genitourinary system tumors or other organ tumors;
- Patients with muscle invasive bladder urothelial carcinoma (≥T2);
- Patients receiving chemotherapy, radiotherapy or immunotherapy within the past 4 weeks (excluding immediate postoperative intravesical chemotherapy);
- Pregnant or lactating women, women of childbearing age who did not use effective contraception, and those who planned to become pregnant during the trial (including the partner of male subjects);
- Known or suspected intraoperative bladder perforation;
- Gross hematuria was present before enrollment, and the surgical wound was suspected to be unhealed or damaged urinary mucosa;
- Patients with cystitis, or previous treatment with other intravesical agents, whose bladder irritation significantly affected the evaluation of the study;
- Patients who had participated in a clinical trial with other drugs within 3 months before enrollment;
- Patients with known opioid or alcohol dependence;
- Patients with any condition considered by the investigators to increase the risk of the subject or interfere with the conduct of the trial;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pseudomonas aeruginosa Group
|
A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study.
The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT.
After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected.
The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes.
The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total.
Patients were followed up every 3 months after surgery.
The last follow-up was completed in February 2025
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recurrence rate
Time Frame: 1 year
|
Recurrence rate is determined on the basis of cystoscopy
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival
Time Frame: 1 year
|
Disease-free survival is defined as the time from the start of study treatment to disease recurrence or death from any cause
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse event
Time Frame: 2 year
|
Adverse events including lower urinary tract symptoms, fever, and gastrointestinal reactions were evaluated according to laboratory and clinical tests (i.e., hematology and blood chemistry, urinalysis, and vital signs) during the observation period
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2023
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
July 26, 2023
First Submitted That Met QC Criteria
July 26, 2023
First Posted (Actual)
August 3, 2023
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 18, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Pseudomonas Infections
- Non-Muscle Invasive Bladder Neoplasms
Other Study ID Numbers
- bks02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
Clinical Trials on Pseudomonas aeruginosa
-
Wuhan Union Hospital, ChinaRecruiting
-
Valneva Austria GmbHCompleted
-
Hospices Civils de LyonCompletedBone and Joint InfectionFrance
-
University of JenaUnknownSinusitis | Cystic Fibrosis With Other ManifestationsGermany
-
Valneva Austria GmbHCompletedPseudomonas Aeruginosa InfectionSpain, Germany, Belgium, Austria, Czech Republic, Hungary
-
Fudan UniversityCompletedMetastatic Breast CancerChina
-
Valneva Austria GmbHCompletedPneumonia, Ventilator-AssociatedAustria
-
Cairo UniversityEl-Galaa Military Medical ComplexUnknown
-
Vanderbilt-Ingram Cancer CenterCompletedMetastatic Breast CancerUnited States
-
Medicenna Therapeutics, Inc.CompletedGlioblastoma | Glioblastoma Multiforme | Grade IV Astrocytoma | Grade IV GliomaUnited States